Key Details
Price
$1.16Annual EPS
-$1.05Annual ROE
-238.61%Beta
0.98Events Calendar
Next earnings date:
May 15, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Apr 14, 2020Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 05, 2018Analyst ratings
Recent major analysts updates
Screeners with MBOT included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for ACCESS-PVI human clinical trial for LIBERTY®.
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.
Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system
FAQ
- What is the primary business of Microbot Medical?
- What is the ticker symbol for Microbot Medical?
- Does Microbot Medical pay dividends?
- What sector is Microbot Medical in?
- What industry is Microbot Medical in?
- What country is Microbot Medical based in?
- When did Microbot Medical go public?
- Is Microbot Medical in the S&P 500?
- Is Microbot Medical in the NASDAQ 100?
- Is Microbot Medical in the Dow Jones?
- When was Microbot Medical's last earnings report?
- When does Microbot Medical report earnings?
- Should I buy Microbot Medical stock now?